Replies to post #11378 on GTC Biotherapeutics (fka GTCB)

[DragonBits]

The correct question would be in theory is there enough of a difference between producing antithrombin Vs FVIII and FIX to make production of antithrombin by PER.C6® cell line impossible or not economically feasible?

One could understand the emphasis on FVIII and FIX since those drugs have a well-established market.

Is there any reason antithrombin couldn't also be produced by this PER.C6® platform?

[DewDiligence]

Crucell’s FV Leiden/Cambridge program has been
moved to the back burner. From #msg-29237602:

>>
Blood Coagulation Factor VL/C: Preclinical work on this program continues but conclusive proof of concept is not expected in the near future.
<<

On their recent CC, CRXL executives hinted that this program may not receive any new funding.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”